MedTrace Logo

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

NCT05201729 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-02-08

No results posted yet for this study

Summary

The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low. Therefore,it is essential to develop new therapies to improve the survival of patients with pancreatic cancer.

Conditions

  • Pancreatic Ductal Adenocarcinoma, PDAC

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Duowu Zou · Ruijin Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05201729 on ClinicalTrials.gov